Stockscreener 앱 받기
3.14
53.17%
1.09
시간 외 거래:
3.43
0.29
+9.24%
전일 마감가:
$2.05
열려 있는:
$2.43
하루 거래량:
30.40M
Relative Volume:
30.10
시가총액:
$201.43M
수익:
$31.25M
순이익/손실:
$-88.48M
주가수익비율:
-2.0258
EPS:
-1.55
순현금흐름:
$-79.63M
1주 성능:
+19.39%
1개월 성능:
+163.87%
6개월 성능:
+163.87%
1년 성능:
+229.04%
1일 변동 폭
$2.29
$3.54
1주일 범위
$2.03
$3.54
52주 변동 폭
$0.77
$3.54
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ACRS | 3.14 | 201.43M | 31.25M | -88.48M | -79.63M | -1.55 |
| TMO | 501.29 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 230.06 | 166.23B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.92 | 36.47B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 191.04 | 34.67B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 419.83 | 34.38B | 3.84B | 866.24M | 792.60M | 9.80 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics, Inc. announced that it expects to receive funding from a group of investors - Marketscreener.com
Aclaris Therapeutics (ACRS): Strategic Alliance with Biosion Ignites 53% Stock Surge - BP Journal
Aclaris stock rallies 53% amid licensing deal, Piper upgrade (NASDAQ:ACRS) - Seeking Alpha
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential - Digital More
Aclaris secures $80 million in private stock sale - Investing.com
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - The Manila Times
Aclaris Therapeutics Announces $80 Million Private Placement - GlobeNewswire
Aclaris Therapeutics Announces Exclusive, Global License - GlobeNewswire
Citadel Advisors LLC Adjusts Position in Aclaris Therapeutics Inc - GuruFocus.com
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Hold at StockNews.com - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Position Boosted by BML Capital Management LLC - MarketBeat
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week - Simply Wall St
News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts - Yahoo Finance
Aclaris stock touches 52-week high at $2.68 amid market fluctuations By Investing.com - Investing.com South Africa
Aclaris stock touches 52-week high at $2.68 amid market fluctuations - Investing.com
FY2024 EPS Estimates for ACRS Reduced by Leerink Partnrs - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by StockNews.com - Defense World
Aclaris Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
Aclaris Therapeutics Reports Positive Q3 2024 Milestones - TipRanks
Aclaris: Q3 Earnings Snapshot - The Washington Post
Aclaris Therapeutics Inc earnings missed by $0.10, revenue topped estimates - Investing.com India
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewswire
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Cross Above 50-Day Moving AverageWhat's Next? - MarketBeat
Contrasting Star Equity (NASDAQ:STRR) and Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc - Yahoo Finance
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLC - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Target Price from Analysts - MarketBeat
Stonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MSN
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
Accenture (NYSE:ACN) PT Raised to $365.00 - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World
Investing in Astrazeneca plc ADR (AZN) Is Getting More Attractive - Knox Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
Metric Deep Dive: Understanding Accenture plc (ACN) Through its Ratios - The Dwinnex
American Century Companies Inc. Boosts Stock Position in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial - Clinical Trials Arena
Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.04%
3.19%
자본화:
|
볼륨(24시간):